On June 3, 2025, Reviva Pharmaceuticals announced that its auditor, Moss Adams, merged with Baker Tilly and resigned, with Baker Tilly appointed as the new auditor effective that same day. The audit reports from Moss Adams for previous years did not contain any adverse opinions, but had a note on going concern uncertainty.